Study of a new drug for relapsed AML with specific genetic changes
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have acute myeloid leukemia (AML) that has returned or not responded to standard treatments.
- Your leukemia must have a specific genetic change: an NPM1 mutation, or a KMT2A or NUP98 rearrangement.
- You cannot have a very high white blood cell count that cannot be controlled.
- Your AML must not be only outside the bone marrow (extramedullary only).
- You must not have active hepatitis, HIV, or other cancer requiring treatment, and you must not have significant heart or liver/kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a Phase 1 trial testing a new drug called BSB-2002 in patients with acute myeloid leukemia (AML) that has come back or stopped responding to previous treatments. The drug is designed specifically for patients whose cancer cells have a particular genetic change (NPM1 mutation) and may help control the cancer by activating the immune system.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This trial tests a new drug (S243249) for people with acute leukemia that has come back or not responded to treatment. It focuses on those with specific gene changes (KMT2A, NUP98, or NPM1c) and aims to see if the drug is safe and effective.
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial tests a new drug, revumenib, combined with strong chemotherapy for people with a specific type of AML (NPM1 mutation). The goal is to see if adding revumenib helps treat the leukemia better than chemo alone.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.